On a preliminary basis, NuVasive (NASDAQ:NUVA)
expects Q1 revenue of $259M – 261M, down over 5% (midpoint) from a year
ago and more than 14% shy of ~$280M consensus due to COVID-19 headwinds
on elective surgical procedures.
2020 guidance withdrawn and temporary cost-cutting measures implemented.
At the end of March, it had more than $500M in cash and $550M available under its credit revolver.
Management will release final results on May 6.
https://seekingalpha.com/news/3560652-nuvasive-sees-decline-in-q1-revenue-pulls-guidance-in-response-to-pandemic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.